A detailed look at the Theranostics Market Segment reveals key differentiations in product types and end-users. By Product Type, the market is typically categorized into:
-
Radiopharmaceuticals (Agents): The highest growth segment, including isotopes like Lutetium-177 and Gallium-68, which are the core therapeutic and diagnostic components.
-
Diagnostic Imaging Equipment: Including systems like PET/CT and SPECT/CT, which are essential for pre-treatment staging and post-treatment monitoring.
-
IVD/Biomarker Screening (Companion Diagnostics): Molecular tests (e.g., PCR, NGS) used to confirm the presence of the specific molecular target (like PSMA) that the therapy is designed to hit.
Focusing on the delivery model, there is little bit change in content from now. The End-User Segment is dominated by Hospitals and Cancer Care Centers, which account for the largest market share due to their integrated nuclear medicine suites, specialized personnel, and high patient volume for complex treatments. The rapid expansion of specialized Theranostics Centers and the critical research conducted by Academic and Research Centers further support the growth within this specialized Theranostics Market Segment. [Theranostics Market Segment]